Opposite effects of opiate agonists on metabolic weight loss in mice

Morphine (M) produced a dose-related decrease in metabolic weight loss (MWL) over a three-hour period, despite the fact that it significantly enhanced locomotor activity in male mice. This conservation of energy was specific to opioid receptors because naltrexone HCl (N) blocked it. These receptors...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropeptides (Edinburgh) 1985-01, Vol.5 (4), p.327-330
Hauptverfasser: Henry, Leah J., Walker, J., Margules, David L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 330
container_issue 4
container_start_page 327
container_title Neuropeptides (Edinburgh)
container_volume 5
creator Henry, Leah J.
Walker, J.
Margules, David L.
description Morphine (M) produced a dose-related decrease in metabolic weight loss (MWL) over a three-hour period, despite the fact that it significantly enhanced locomotor activity in male mice. This conservation of energy was specific to opioid receptors because naltrexone HCl (N) blocked it. These receptors were localized mainly to the periphery because a form of N that does not enter the brain, MR2663 BR (QN) eliminated the conservation response and instead increased MWL. The increase in MWL induced by M plus QN was blocked by MR2266 (MR), a specific kappa receptor antagonist. We suggest that this increase is due to the unmasking of a kappa opioid system located in the brain that acts to enhance energy expenditure. In support of this idea, administration of the kappa receptor agonist U-50, 488H (U) produced a dose-related increase in MWL to levels nearly twice that of saline controls, while markedly reducing locomotor activity. These actions were blocked by MR but not by N. They were not blocked by QN and this suggests they originate mainly in the brain. Increasing amounts of M caused increasing inhibition of metabolic weight loss induced by a constant amount of U. This supports the idea of an antagonistic relationship between the two opioid systems.
doi_str_mv 10.1016/0143-4179(85)90019-8
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76138638</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0143417985900198</els_id><sourcerecordid>76138638</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-3a14a09ca0f6a05c5cb06d50ca61b42ab91c5689e68f8da9b52de84ea9a133813</originalsourceid><addsrcrecordid>eNqFkE9PwzAMxSMEGmPwDUDqCcGhEDdJm1yQ0PgrTdoFzlGauiOobUrTgfj2tGzaEU62_J6f5R8hp0CvgEJ6TYGzmEOmLqS4VJSCiuUemYJgSZxkUuyT6c5ySI5CeKeU8kTKCZnwsQU6JXfLtvXB9RhhWaLtQ-TLyLfODBOz8o0L46iJauxN7itnoy90q7c-qnwIkRsEZ_GYHJSmCniyrTPy-nD_Mn-KF8vH5_ntIrZMyj5mBrihyhpapoYKK2xO00JQa1LIeWJyBVakUmEqS1kYlYukQMnRKAOMSWAzcr7JbTv_scbQ69oFi1VlGvTroLMUmEyZ_NcIHATnNBuMfGO03fBPh6VuO1eb7lsD1SNlPSLUI0Ithf6lrMf8s23-Oq-x2C1tsQ76zUbHgcanw04H67CxWLhugKwL7_4-8AMP-YsP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14154407</pqid></control><display><type>article</type><title>Opposite effects of opiate agonists on metabolic weight loss in mice</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Henry, Leah J. ; Walker, J. ; Margules, David L.</creator><creatorcontrib>Henry, Leah J. ; Walker, J. ; Margules, David L.</creatorcontrib><description>Morphine (M) produced a dose-related decrease in metabolic weight loss (MWL) over a three-hour period, despite the fact that it significantly enhanced locomotor activity in male mice. This conservation of energy was specific to opioid receptors because naltrexone HCl (N) blocked it. These receptors were localized mainly to the periphery because a form of N that does not enter the brain, MR2663 BR (QN) eliminated the conservation response and instead increased MWL. The increase in MWL induced by M plus QN was blocked by MR2266 (MR), a specific kappa receptor antagonist. We suggest that this increase is due to the unmasking of a kappa opioid system located in the brain that acts to enhance energy expenditure. In support of this idea, administration of the kappa receptor agonist U-50, 488H (U) produced a dose-related increase in MWL to levels nearly twice that of saline controls, while markedly reducing locomotor activity. These actions were blocked by MR but not by N. They were not blocked by QN and this suggests they originate mainly in the brain. Increasing amounts of M caused increasing inhibition of metabolic weight loss induced by a constant amount of U. This supports the idea of an antagonistic relationship between the two opioid systems.</description><identifier>ISSN: 0143-4179</identifier><identifier>EISSN: 1532-2785</identifier><identifier>DOI: 10.1016/0143-4179(85)90019-8</identifier><identifier>PMID: 4000410</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer ; Animals ; Body Weight - drug effects ; Energy Metabolism - drug effects ; Male ; Mice ; Mice, Inbred C57BL ; Morphine - pharmacology ; Motor Activity - drug effects ; Pyrrolidines - pharmacology</subject><ispartof>Neuropeptides (Edinburgh), 1985-01, Vol.5 (4), p.327-330</ispartof><rights>1985</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c388t-3a14a09ca0f6a05c5cb06d50ca61b42ab91c5689e68f8da9b52de84ea9a133813</citedby><cites>FETCH-LOGICAL-c388t-3a14a09ca0f6a05c5cb06d50ca61b42ab91c5689e68f8da9b52de84ea9a133813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0143417985900198$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/4000410$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Henry, Leah J.</creatorcontrib><creatorcontrib>Walker, J.</creatorcontrib><creatorcontrib>Margules, David L.</creatorcontrib><title>Opposite effects of opiate agonists on metabolic weight loss in mice</title><title>Neuropeptides (Edinburgh)</title><addtitle>Neuropeptides</addtitle><description>Morphine (M) produced a dose-related decrease in metabolic weight loss (MWL) over a three-hour period, despite the fact that it significantly enhanced locomotor activity in male mice. This conservation of energy was specific to opioid receptors because naltrexone HCl (N) blocked it. These receptors were localized mainly to the periphery because a form of N that does not enter the brain, MR2663 BR (QN) eliminated the conservation response and instead increased MWL. The increase in MWL induced by M plus QN was blocked by MR2266 (MR), a specific kappa receptor antagonist. We suggest that this increase is due to the unmasking of a kappa opioid system located in the brain that acts to enhance energy expenditure. In support of this idea, administration of the kappa receptor agonist U-50, 488H (U) produced a dose-related increase in MWL to levels nearly twice that of saline controls, while markedly reducing locomotor activity. These actions were blocked by MR but not by N. They were not blocked by QN and this suggests they originate mainly in the brain. Increasing amounts of M caused increasing inhibition of metabolic weight loss induced by a constant amount of U. This supports the idea of an antagonistic relationship between the two opioid systems.</description><subject>3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer</subject><subject>Animals</subject><subject>Body Weight - drug effects</subject><subject>Energy Metabolism - drug effects</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Morphine - pharmacology</subject><subject>Motor Activity - drug effects</subject><subject>Pyrrolidines - pharmacology</subject><issn>0143-4179</issn><issn>1532-2785</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE9PwzAMxSMEGmPwDUDqCcGhEDdJm1yQ0PgrTdoFzlGauiOobUrTgfj2tGzaEU62_J6f5R8hp0CvgEJ6TYGzmEOmLqS4VJSCiuUemYJgSZxkUuyT6c5ySI5CeKeU8kTKCZnwsQU6JXfLtvXB9RhhWaLtQ-TLyLfODBOz8o0L46iJauxN7itnoy90q7c-qnwIkRsEZ_GYHJSmCniyrTPy-nD_Mn-KF8vH5_ntIrZMyj5mBrihyhpapoYKK2xO00JQa1LIeWJyBVakUmEqS1kYlYukQMnRKAOMSWAzcr7JbTv_scbQ69oFi1VlGvTroLMUmEyZ_NcIHATnNBuMfGO03fBPh6VuO1eb7lsD1SNlPSLUI0Ithf6lrMf8s23-Oq-x2C1tsQ76zUbHgcanw04H67CxWLhugKwL7_4-8AMP-YsP</recordid><startdate>19850101</startdate><enddate>19850101</enddate><creator>Henry, Leah J.</creator><creator>Walker, J.</creator><creator>Margules, David L.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>19850101</creationdate><title>Opposite effects of opiate agonists on metabolic weight loss in mice</title><author>Henry, Leah J. ; Walker, J. ; Margules, David L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-3a14a09ca0f6a05c5cb06d50ca61b42ab91c5689e68f8da9b52de84ea9a133813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer</topic><topic>Animals</topic><topic>Body Weight - drug effects</topic><topic>Energy Metabolism - drug effects</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Morphine - pharmacology</topic><topic>Motor Activity - drug effects</topic><topic>Pyrrolidines - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Henry, Leah J.</creatorcontrib><creatorcontrib>Walker, J.</creatorcontrib><creatorcontrib>Margules, David L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Neuropeptides (Edinburgh)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Henry, Leah J.</au><au>Walker, J.</au><au>Margules, David L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Opposite effects of opiate agonists on metabolic weight loss in mice</atitle><jtitle>Neuropeptides (Edinburgh)</jtitle><addtitle>Neuropeptides</addtitle><date>1985-01-01</date><risdate>1985</risdate><volume>5</volume><issue>4</issue><spage>327</spage><epage>330</epage><pages>327-330</pages><issn>0143-4179</issn><eissn>1532-2785</eissn><abstract>Morphine (M) produced a dose-related decrease in metabolic weight loss (MWL) over a three-hour period, despite the fact that it significantly enhanced locomotor activity in male mice. This conservation of energy was specific to opioid receptors because naltrexone HCl (N) blocked it. These receptors were localized mainly to the periphery because a form of N that does not enter the brain, MR2663 BR (QN) eliminated the conservation response and instead increased MWL. The increase in MWL induced by M plus QN was blocked by MR2266 (MR), a specific kappa receptor antagonist. We suggest that this increase is due to the unmasking of a kappa opioid system located in the brain that acts to enhance energy expenditure. In support of this idea, administration of the kappa receptor agonist U-50, 488H (U) produced a dose-related increase in MWL to levels nearly twice that of saline controls, while markedly reducing locomotor activity. These actions were blocked by MR but not by N. They were not blocked by QN and this suggests they originate mainly in the brain. Increasing amounts of M caused increasing inhibition of metabolic weight loss induced by a constant amount of U. This supports the idea of an antagonistic relationship between the two opioid systems.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>4000410</pmid><doi>10.1016/0143-4179(85)90019-8</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0143-4179
ispartof Neuropeptides (Edinburgh), 1985-01, Vol.5 (4), p.327-330
issn 0143-4179
1532-2785
language eng
recordid cdi_proquest_miscellaneous_76138638
source MEDLINE; Elsevier ScienceDirect Journals
subjects 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
Animals
Body Weight - drug effects
Energy Metabolism - drug effects
Male
Mice
Mice, Inbred C57BL
Morphine - pharmacology
Motor Activity - drug effects
Pyrrolidines - pharmacology
title Opposite effects of opiate agonists on metabolic weight loss in mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T03%3A48%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Opposite%20effects%20of%20opiate%20agonists%20on%20metabolic%20weight%20loss%20in%20mice&rft.jtitle=Neuropeptides%20(Edinburgh)&rft.au=Henry,%20Leah%20J.&rft.date=1985-01-01&rft.volume=5&rft.issue=4&rft.spage=327&rft.epage=330&rft.pages=327-330&rft.issn=0143-4179&rft.eissn=1532-2785&rft_id=info:doi/10.1016/0143-4179(85)90019-8&rft_dat=%3Cproquest_cross%3E76138638%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=14154407&rft_id=info:pmid/4000410&rft_els_id=0143417985900198&rfr_iscdi=true